The Division of Medical Oncology, School of Pharmacy, and the Bone Marrow Transplant Program sponsor an interdisciplinary postdoctoral training program in the """"""""Clinical Pharmacology of Antineoplastic Agents."""""""" The goal of this training program is to provide individuals with the complex skills necessary to develop antineoplastic agents, evaluate their properties, design clinical studies, and move these agents through the regulatory agencies into national trials. The preceptors involved in this training believe that there is an important need for scientists who are trained in the practical evaluation of chemotherapeutic agents to facilitate the movement of these agents from the laboratory bench to the bedside. ? ? The program includes 2-3 years of basic laboratory research training, required core courses, available lecture series and elective courses. An Executive Committee consisting of the directors of the three cooperating units will administer it, and a Mentor's Committee of three faculty members will monitor student progress. Trainees will be required to write a NIH style RO-1, give local research seminars, attend national meetings, and publish articles in peer-reviewed journals. The trainees will be evaluated on a yearly basis by the Program Director. ? ? The first four years of this training grant have been extremely successful. Of the eight trainees that have completed the program, three have joined academic medical centers and three have gone into cancer drug development in industry. Forty percent of the trainees have been women. One Hispanic male and almost equal numbers of M.D.s and Ph.D.s were trained. The training grant faculty taught two new core courses, one in cancer drug pharmacology and the other in cancer biology that became part of the Medical School curriculum. ? ? This unique training program provides an interactive environment in which M.D.s and Ph.Ds involved in all phases of antineoplastic agent development will train individuals in the preclinical and clinical science necessary to take anticancer agents from the bench to the bedside. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA079446-08
Application #
7270561
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
1999-09-01
Project End
2010-06-30
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
8
Fiscal Year
2007
Total Cost
$166,956
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Diamond, Jennifer R; Eckhardt, S Gail; Tan, Aik Choon et al. (2013) Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models. Clin Cancer Res 19:291-303
Morelli, M Pia; Tentler, John J; Kulikowski, Gillian N et al. (2012) Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models. Clin Cancer Res 18:1051-62
Serkova, Natalie J; Renner, Brandon; Larsen, Brian A et al. (2010) Renal inflammation: targeted iron oxide nanoparticles for molecular MR imaging in mice. Radiology 255:517-26
Pitts, Todd M; Tan, Aik Choon; Kulikowski, Gillian N et al. (2010) Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. Clin Cancer Res 16:3193-204
Tentler, John J; Nallapareddy, Sujatha; Tan, Aik Choon et al. (2010) Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. Mol Cancer Ther 9:3351-62
Diamond, Jennifer R; Finlayson, Christina A; Borges, Virginia F (2009) Hepatic complications of breast cancer. Lancet Oncol 10:615-21
Hattar, Rhonda; Maller, Ori; McDaniel, Shauntae et al. (2009) Tamoxifen induces pleiotrophic changes in mammary stroma resulting in extracellular matrix that suppresses transformed phenotypes. Breast Cancer Res 11:R5
Medeiros, B C; Landau, H J; Morrow, M et al. (2007) The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines. Leukemia 21:739-46
Flaig, Thomas W; Su, Lih-Jen; Harrison, Gail et al. (2007) Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells. Int J Cancer 120:2028-33
Garzon-Rodriguez, William; Koval, Rebecca L; Chongprasert, Suchart et al. (2004) Optimizing storage stability of lyophilized recombinant human interleukin-11 with disaccharide/hydroxyethyl starch mixtures. J Pharm Sci 93:684-96

Showing the most recent 10 out of 19 publications